James Pipkin
Vice President, New Product Development at Ligand Pharmaceuticals
About
VP of New Product Development focused on applications and IP for the Captisol cyclodextrin drug-delivery technology, joining Ligand via the 2011 CyDex acquisition. He previously directed CMC services at Oread Laboratories and was a research fellow at Merck.
Colleagues at Ligand Pharmaceuticals
Andrew Reardon
Chief Legal Officer at Ligand Pharmaceuticals
Karen Reeves
Senior Vice President, Investments and Head of Clinical Strategy at Ligand Pharmaceuticals
Keith Marschke
Senior Vice President, Biology and Scientific Affairs at Ligand Pharmaceuticals
Lauren Hay
Vice President, Portfolio Strategy and Investments at Ligand Pharmaceuticals
Lee Brown
Vice President, Investments and Business Development at Ligand Pharmaceuticals
Marjorie Fackovec
Head of People Operations at Ligand Pharmaceuticals
Michael Vigilante
Vice President, Investments and Business Development at Ligand Pharmaceuticals
Paul J. Hadden
Senior Vice President, Investments and Business Development at Ligand Pharmaceuticals